William Moore Email & Phone Number

Pittsboro, Nc, Us

 Currently leading the post-merger integration of Propella the Propella organization and programs into Astellas, including PRL-02 global development strategies

Successfully accomplished a highly successful investor exit and significant ROI through the acquisition of Propella by Astellas Pharma for approximately $175M cash up-front; deal was recognized by the Corporate Growth Association as the #1 transaction in the Washington, DC area in the $50-$250M category in 2023★ Provided a positive ROI multiple to the Propella family office investor and a cash payout to all shareholders★ Led a Board-approved dual track IPO / M&A exit strategy; successfully secured two written $40M+ Series A term sheets from distinct blue-chip VC syndicates★ Led the spinout of Propella from Vizuri Health Sciences to focus on the development of the potential best-in-class prostate cancer therapeutic, PRL-02★ Co-invented, filed the IND and initiated a Ph 1/2a study of PRL-02, a novel long-acting injection for advanced prostate cancer★ Led the U.S. development of PRL-02 from product concept into Ph 1/2 proof-of concept studies prior to the acquisition by Astellas★ Presented PRL-02 nonclinical and clinical results at the 2022, 2023 and 2024 ASCO GU, 2022 ESMO and 2021 and 2023 ASCO medical conferences★ Led and organized Board of Director meetings and activities, while managing a focused and committed executive management team

★ Co-invented PRL-02, a patented CYP17 lyase-selective inhibitor for the the treatment of treatment prostrate cancer, which to the creation and spinout of Propella Therapeutics from Vizuri.★ Filed the US IND for CGS-200-5, a topical prescription strength formulation of capsaicin for the the treatment of pain due to osteoarthritis of the knee. ★ Completed a U.S. Phase 2 knee osteoarthritis pain study; results presented at the 2019 American College of Rheumatology meeting; subsequently new ACR guideline conditionally recommends topical capsaicin for the treatment of OA.★ Reduced operating expenses by 40% and transitioned Vizuri to an operating company through OTC retail launch of PainBloc24®. ★ Increased month-to-month OTC sales turn while expanding retail distribution; strengthened sales and marketing organization while reducing expense by >60%.★ Initiated research on new innovative internal Rx and OTC products, while evaluating external product opportunities through in-licensing / acquisition.☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲ABOUT VIZURI HEALTH SCIENCES, LLCVizuri was a family-owned, OTC and pharmaceutical development company with a focus on safe, new products for the management of nerve pain.

★ Launched a consulting firm and built a book of business comprising investors, companies in the biotechnology and pharmaceutical verticals, and academic clients.★ Client engagements included work with a Health Sciences corporation to use its patented and proprietary formulation technologies to improve the efficacy or safety of existing medications.★ Advised the Health Sciences client on the optimal use of capital and development strategies to drive commercialization.★ Retained by a venture capital firm to provide due diligence on two target companies now in their portfolio.★ Assessed start-up businesses and provided commercialization and fund-raising strategies to multiple companies spun out of several large local universities.☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲ABOUT FEARRINGTON BIO ADVISORY LLCFearrington Bio Advisory LLC is a consulting firm that serves investors, companies in the biotechnology and pharmaceutical verticals, and academic clients in the areas of research, investment guidance, and due diligence.

★ As founding CEO, closed a $6M financing round in late 2014, enabling the spinout of Innocrin from Viamet Pharmaceuticals and then completed a $28M private equity financing round in 1Q2015.★ Secured approximately $3M in funding from the National Cancer Institute and $1M in funding from the Prostate Cancer Foundation.★ Managed the discovery, development, and regulatory filings for the oral CYP17 lyase inhibitor drug candidate, seviteronel.★ Initiated a breast cancer clinical development program while advancing seviteronel for the treatment of castration-resistant prostate cancer.★ Navigated seviteronel development to Phase II clinical studies while established strong relationships with clinical investigators, pharmaceutical executives and other key stakeholders.★ Was responsible for all company operations and added employees as needed to build out clinical development, regulatory, manufacturing, business development, finance, legal, and communications.☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲ABOUT INNOCRIN PHARMACEUTICALS, LLCInnocrin is a privately-held, clinical stage pharmaceutical company that develops best-in-class oral, selective CYP17 lyase inhibitors for the treatment of breast cancer

2016 Company Pitch at CED Life Sciences Meeting

★ Responsible for directing development nominations and discovery, preclinical safety and efficacy, and CMC and regulatory activities for oncology (VT-464) and antifungal (VT-1161, VT-1129, VT-1598) NCEs.★ Led teams of R&D and regulatory affairs professionals from discovery through Phase 2 development.★ Hosted conferences with major medical and scientific stakeholders, as well as Board of Director meetings, to showcase program highlights.★ Developed separate partnerships with the National Institutes of Health and Dow AgroSciences to accelerate the development of VT-1129 and a proprietary antifungal, respectively, generating over $8MM in revenue.☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲ABOUT VIAMET PHARMACEUTICALSThe Viamet antifungal assets were acquired by NovaQuest Capital Management, L.L.C. in 2018 following successful completion of Phase 2b clinical trials for the treatment of recurrent vulvovaginal candidiasis and onychomycosis. Following successful completion of multiple Ph 3 studies, VT-1161 (aka VIVJOA) is currently the only FDA-approved treatment for recurrent vulvovaginal candidiasis.

Description:★ Served the needs of corporate, financial, and academic clients in the areas of business development, R&D strategy, due diligence, and finance.★ Contributed to the launch of new start-up and spin-out businesses.★ Negotiated licenses, authoring business plans, and securing multimillion dollar rounds of Series A funding on behalf of clients.★ Recipient of the Senior Executive Mentor Award from Temple Fox School of Business.☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲ABOUT MOORE CONSULTING LLCMoore Consulting engages in advisory services in the areas of of business development, R&D strategy, due diligence, and finance.

Us

★ Founded and evolved a 75-employee organization from a computational fragment-based, chemistry company into a clinical business dedicated to the discovery of cancer and inflammatory treatments.★ Directed legal affairs, business development, and R&D.★ Negotiated out-licensing deals with Amgen, Dow, Dupont, Eli Lilly, Ono, and Scios.☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲☲ABOUT LOCUS PHARMACEUTICALSLocus Pharmaceuticals, Inc. is a privately held drug discovery and development biotechnology company creating novel therapeutics using its patented drug design technology. Locus was founded in 2000 based on its platform technology, entered into multiple drug discovery collaboration projects with pharmaceutical partners, and built a pipeline of early clinical development assets for cancer and inflammatory indications.

Us

★ Responsible for management and integration of 220-person genomics / genetics organization into cancer target discovery Division of public drug development organization★ Reorganized the Division into effective and collaborative teams while elevating individual scientist visibility and retaining key personnel★ Initiated and managed corporate alliances with Parke-Davis and Roche

★ Scientific leadership role in support of R&D, new BD initiatives, fundraising, and an IPO★ Established molecular biology, protein expression, high through-put screening, genomics, enzymology groups and directed 40 scientists★ Was team leader for revenue-generating partnerships with Bayer, Bristol Meryers Squibb, Merck, Pharmacia-Upjohn, and SmithKline Beecham

★ Led anti-cancer and anti-hypercholesterolemia projects while reporting to the to the Head of Chemical Sciences★ Led research teams focused on focused on discovery of inhibitors of cholesterol biosynthetic pathway and cancer proteases

★ Assistant professor in the Biochemistry Dept., research focused on the glutathione function and disregulation★ Hired as a post-doc within the competitive Winston Foundation Fellow program (Alton Meister, MD, mentor)

Doctor Of Philosophy - Phd, Chemistry

Ph.D., Chemistry

B.S., Chemistry

Bachelor Of Science - Bs, Chemistry